Calcium Channel

Ca2+ channel agonist 1 activates N-type Ca2+ channels and inhibits Cdk2 (EC50: 14.23 μM/3.34 μM) for motor nerve issues.

L-Ascorbic acid sodium salt (Vitamin C sodium salt) is a more bioavailable form of vitamin C that is an alternative to taking ascorbic acid as a supplement.

8-Bromo-cGMP sodium: PKG activator, eases pain, dilates vessels, reduces Ca2+ currents & insulin release.

Fenoverine (Spasmopriv) has antispasmodic activity and can be used to study gastrointestinal spasms.

2,3-Dihydroxy-4-methoxyacetophenone (2',3'-Dihydroxy-4'-methoxyacetophenone) is a natural product,it improves cognitive function and may be helpful for the

Stability Light Sensitive Applications 1R,3R,αR-Deltamethrin is an isomer of Deltamethrin (D230700), a synthetic pyrethroid insecticide, which acts as a potent inhibitor of calcineurin (protein phosphatase 2B) and has an IC50 of about 100pM. This inhibition action results in cellular hyperexcitability by causing non-mutated calcium channels to remain open for an extended period of time allowing an abundance of Ca2+ to enter the cell. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Kavlock, R., et al.: J. Environ. Pathol. Toxicol., 2, 751 (1979), Enan, E., et al.: Biochem. Pharmacol., 43, 1777 (1992), Tan, J., et al.: Mol. Biol., 32, 445 (2002),

18:0 LYSO-PE is a compound that induces an increase in [Ca2+]i and can be used as a phospholipid (PL) standard for lipid analysis by electrospray mass spectrometry (ESI-MS)/MS.

TMDJ-035 is a selective inhibitor of the RyR2 (ryanodine receptor 2).

Emopamil, a calcium channel inhibitor, reduces neuronal damage caused by ischemia.

Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is a dione-type anticonvulsant with antiepileptic activity.

Applications 2-[(3-Nitrophenyl)methylene]-3-oxo-butanoic Acid 2-[(3,3-Diphenylpropyl)methylamino]-1,1-dimethylethyl Ester Hydrochloride is an intermediate in synthesizing 5-Ethyl-demethyl Lercanidipine (E913200), which is an impurity of Lercanidipine (L179000), a dihydropyridine calcium channel blocker. References Bianchi, G., et al.: Pharmacol. Res., 21, 193 (1989); Rimoldi, E., et al.: Acta Therap., 200, 23 (1994); Argekar, A., et al.: J. Pharm. Biomed. Anal., 21, 1137 (2000);

Stability Hygroscopic Applications 4-Defluoro 2-Fluoro Flunarizine Dihydrochloride is an impurity of Flunarizine(F455200, Dihydrochloride), which is a calcium channel blocker. Flunarizine is a fluorinated derivative of Cinnarizine and a vasodilator (cerebral and peripheral). References Desmedt, L.K., et al.: Arzneim.-Forsch., 25, 1408 (1975), Godfraind, T., et al.: Eur. J. Pharmacol., 53, 273 (1979), Nihard, P., et al.: Angiology, 33, 37 (1982), Holmes, B., et al.: Drugs, 27, 6 (1984)

Amlodipine (UK-48340) is a synthetic dihydropyridine and a calcium channel blocker with antihypertensive and antianginal properties.

Brompheniramine maleate (Dimotane) is an antagonist against histamine H1 receptors.

Hexadecylphosphoserine is a type of phospholipid molecule that incorporates a long-chain alkyl group (hexadecyl) and a phosphatidylserine group, granting it high affinity for cell membranes. This compound exhibits antitumor activity by modulating [Ca++]i and related signaling pathways, making it useful for breast cancer research.

AChE/BChE-IN-21 is an antagonist of the histamine H3 receptor, a calcium channel blocker, and an acetylcholinesterase inhibitor. It exhibits neuroprotective activities against H2O2 and Aβ1-40, and can restore cognitive functions in AD mice.

Bay K 8644 (SQ 28,873) is a potent, selective activator of L-type Ca2+ channel with IC50 of 17.3 nM.

Norfluoxetine Hydrochloride (Norfluoxetine HCl) is an active metabolite of fluoxetine. Fluoxetine is an antidepressant drug.

Applications A novel calcium channel antagonist; cardiovascular agent. References Matsumori, A., et al.: Circulation, 66, 355 (1982), Roberts, W., et al.: Am. J. Cardiol., 60, 1340 (1987), Uehara, Y., et al.: J. Cardiovasc. Pharmacol., 23, 970 (1994), Kim, C., et al.: Cardiovasc. Drugs Ther., 13, 455 (1999), Watanabe, K., et al.: Br. J. Pharmacol., 130, 1489 (2000),